Form 4: ALNY EVP Sells Shares After PSU Vesting

Alnylam Pharmaceuticals EVP Chief R&D, Pushkal Garg, sold shares following the vesting of performance-based stock units and to cover tax obligations.

Summary

• Pushkal Garg, EVP Chief R&D at Alnylam Pharmaceuticals, Inc. (ALNY), acquired 2,851 shares of common stock on August 15, 2025, at a price of $0.0.
• This acquisition resulted from the vesting of 30% of a performance-based stock unit (PSU) granted on March 1, 2024, due to the achievement of a clinical milestone.
• On August 18, 2025, Garg sold a total of 1,396 shares of common stock at weighted average prices ranging from $447.98 to $455.82. These sales were mandatory "sell-to-cover" transactions to meet minimum statutory tax withholding obligations upon the vesting and settlement of restricted stock units granted on March 1, 2024.
• On August 19, 2025, Garg sold an additional 1,455 shares of common stock at weighted average prices ranging from $455.41 to $461.74. These sales were executed under a Rule 10b5-1(c) trading plan adopted on September 11, 2024.
• Following these transactions, Garg directly holds 20,221 shares of common stock.
• Garg also holds 431 shares indirectly through a managed 401(k) account and 250 shares indirectly through a trust, for which beneficial ownership is disclaimed.

Sentiment

Score: 6

Explanation: The filing indicates a positive event (clinical milestone achievement leading to PSU vesting) but also routine insider sales, some for tax purposes and others under a pre-arranged plan. The sales are not indicative of a negative outlook, but rather standard compensation management. The net effect on sentiment is neutral to slightly positive due to the milestone.

Positives

• Vesting of 2,851 performance-based stock units (PSUs) on August 15, 2025, indicating the achievement of a clinical milestone.
• The clinical milestone achievement led to the vesting of 30% of the shares subject to the PSU.

Negatives

• Sales of 1,396 shares on August 18, 2025, were mandatory "sell-to-cover" for tax withholding obligations.
• Sales of 1,455 shares on August 19, 2025, were executed under a pre-arranged trading plan, which represents an insider reducing their direct stake.

Future Outlook

NA

Industry Context

This Form 4 filing details routine insider transactions for a biotechnology company executive. The vesting of performance-based stock units tied to a clinical milestone is common in the pharmaceutical industry, reflecting progress in drug development. The subsequent sales, particularly those for tax withholding and under a 10b5-1 plan, are standard practices for executives managing equity compensation.

Comparison to Industry Standards

• The vesting of performance-based stock units upon achievement of a clinical milestone is a standard compensation practice in the biotechnology and pharmaceutical sectors, aligning executive incentives with R&D success.
• The use of Rule 10b5-1 trading plans for pre-scheduled stock sales is a common compliance measure for insiders across all industries, including biotech, to avoid accusations of trading on material non-public information.
• Mandatory sell-to-cover provisions for tax obligations are also standard for equity compensation in publicly traded companies.

Stakeholder Impact

• Shareholders: The vesting of PSUs due to a clinical milestone could be seen as positive, indicating R&D progress. The sales are routine and unlikely to significantly impact shareholder perception beyond normal insider compensation management.
• Employees: The vesting of PSUs demonstrates the company's commitment to performance-based incentives, which could be positive for employee morale and retention, especially for R&D staff.

Next Steps

• The reporting person will provide information regarding the number of shares sold at each price within the reported ranges upon request to the issuer, any security holder, or the SEC staff.

Key Dates

Recommendation

This Form 4 filing primarily details routine insider transactions related to executive compensation, including the vesting of performance-based stock units due to a clinical milestone and subsequent sales for tax obligations and under a pre-arranged trading plan. While the clinical milestone is a positive indicator of R&D progress, the sales themselves are standard and do not suggest a change in the executive's long-term view of the company. There is no new material information that would warrant a change in investment thesis based solely on this filing. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive operational or financial updates.

Keywords

Alnylam Pharmaceuticals, ALNY, SEC Form 4, Insider Trading, Stock Sales, Performance Stock Units, PSU Vesting, Rule 10b5-1, Tax Withholding, Biotechnology, Pharmaceuticals